Cargando…
Network Pharmacology and Molecular Docking–Based Investigation: Prunus mume Against Colorectal Cancer via Silencing RelA Expression
Colorectal cancer (CRC) is one of the most pervasive cancers in the human disease spectrum worldwide, ranked the second most common cause of cancer death by the end of 2020. Prunus mume (PM) is an essential traditional Chinese medicine for the adjuvant treatment of solid tumors, including CRC. In th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640358/ https://www.ncbi.nlm.nih.gov/pubmed/34867383 http://dx.doi.org/10.3389/fphar.2021.761980 |
_version_ | 1784609325771128832 |
---|---|
author | Zhou, Minfeng Li, Jinxiao Luo, Dan Zhang, Haiming Yu, Zhaomin Chen, Youlin Li, Qiumeng Liang, Fengxia Chen, Rui |
author_facet | Zhou, Minfeng Li, Jinxiao Luo, Dan Zhang, Haiming Yu, Zhaomin Chen, Youlin Li, Qiumeng Liang, Fengxia Chen, Rui |
author_sort | Zhou, Minfeng |
collection | PubMed |
description | Colorectal cancer (CRC) is one of the most pervasive cancers in the human disease spectrum worldwide, ranked the second most common cause of cancer death by the end of 2020. Prunus mume (PM) is an essential traditional Chinese medicine for the adjuvant treatment of solid tumors, including CRC. In the current study, we utilize means of network pharmacology, molecular docking, and multilayer experimental verification to research mechanism. The five bioactive compounds and a total of eight critical differentially expressed genes are screened out using the bioinformatics approaches of Cytoscape software, String database, Gene Ontology analysis, Kyoto Encyclopedia of Genes and Genomes pathways, and molecular docking. RelA has been proven to be highly expressed in CRC. Experiments in vitro have shown that kaempferol, the main active component of PM, dramatically inhibited the growth, migration, and invasion of CRC cells, and experiments in vivo have shown that PM effectively delays CRC formation and improves the survival cycle of mice. Further analysis shows that PM inhibits the CRC progression by down-regulating the expression level of RelA, Bax, caspase 3, caspase 9, and EGFR in CRC. PM and its extract are potentially effective therapeutics for the treatment of CRC via the RelA/nuclear factor κB signaling pathway. |
format | Online Article Text |
id | pubmed-8640358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86403582021-12-04 Network Pharmacology and Molecular Docking–Based Investigation: Prunus mume Against Colorectal Cancer via Silencing RelA Expression Zhou, Minfeng Li, Jinxiao Luo, Dan Zhang, Haiming Yu, Zhaomin Chen, Youlin Li, Qiumeng Liang, Fengxia Chen, Rui Front Pharmacol Pharmacology Colorectal cancer (CRC) is one of the most pervasive cancers in the human disease spectrum worldwide, ranked the second most common cause of cancer death by the end of 2020. Prunus mume (PM) is an essential traditional Chinese medicine for the adjuvant treatment of solid tumors, including CRC. In the current study, we utilize means of network pharmacology, molecular docking, and multilayer experimental verification to research mechanism. The five bioactive compounds and a total of eight critical differentially expressed genes are screened out using the bioinformatics approaches of Cytoscape software, String database, Gene Ontology analysis, Kyoto Encyclopedia of Genes and Genomes pathways, and molecular docking. RelA has been proven to be highly expressed in CRC. Experiments in vitro have shown that kaempferol, the main active component of PM, dramatically inhibited the growth, migration, and invasion of CRC cells, and experiments in vivo have shown that PM effectively delays CRC formation and improves the survival cycle of mice. Further analysis shows that PM inhibits the CRC progression by down-regulating the expression level of RelA, Bax, caspase 3, caspase 9, and EGFR in CRC. PM and its extract are potentially effective therapeutics for the treatment of CRC via the RelA/nuclear factor κB signaling pathway. Frontiers Media S.A. 2021-11-19 /pmc/articles/PMC8640358/ /pubmed/34867383 http://dx.doi.org/10.3389/fphar.2021.761980 Text en Copyright © 2021 Zhou, Li, Luo, Zhang, Yu, Chen, Li, Liang and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhou, Minfeng Li, Jinxiao Luo, Dan Zhang, Haiming Yu, Zhaomin Chen, Youlin Li, Qiumeng Liang, Fengxia Chen, Rui Network Pharmacology and Molecular Docking–Based Investigation: Prunus mume Against Colorectal Cancer via Silencing RelA Expression |
title | Network Pharmacology and Molecular Docking–Based Investigation: Prunus mume Against Colorectal Cancer via Silencing RelA Expression |
title_full | Network Pharmacology and Molecular Docking–Based Investigation: Prunus mume Against Colorectal Cancer via Silencing RelA Expression |
title_fullStr | Network Pharmacology and Molecular Docking–Based Investigation: Prunus mume Against Colorectal Cancer via Silencing RelA Expression |
title_full_unstemmed | Network Pharmacology and Molecular Docking–Based Investigation: Prunus mume Against Colorectal Cancer via Silencing RelA Expression |
title_short | Network Pharmacology and Molecular Docking–Based Investigation: Prunus mume Against Colorectal Cancer via Silencing RelA Expression |
title_sort | network pharmacology and molecular docking–based investigation: prunus mume against colorectal cancer via silencing rela expression |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640358/ https://www.ncbi.nlm.nih.gov/pubmed/34867383 http://dx.doi.org/10.3389/fphar.2021.761980 |
work_keys_str_mv | AT zhouminfeng networkpharmacologyandmoleculardockingbasedinvestigationprunusmumeagainstcolorectalcancerviasilencingrelaexpression AT lijinxiao networkpharmacologyandmoleculardockingbasedinvestigationprunusmumeagainstcolorectalcancerviasilencingrelaexpression AT luodan networkpharmacologyandmoleculardockingbasedinvestigationprunusmumeagainstcolorectalcancerviasilencingrelaexpression AT zhanghaiming networkpharmacologyandmoleculardockingbasedinvestigationprunusmumeagainstcolorectalcancerviasilencingrelaexpression AT yuzhaomin networkpharmacologyandmoleculardockingbasedinvestigationprunusmumeagainstcolorectalcancerviasilencingrelaexpression AT chenyoulin networkpharmacologyandmoleculardockingbasedinvestigationprunusmumeagainstcolorectalcancerviasilencingrelaexpression AT liqiumeng networkpharmacologyandmoleculardockingbasedinvestigationprunusmumeagainstcolorectalcancerviasilencingrelaexpression AT liangfengxia networkpharmacologyandmoleculardockingbasedinvestigationprunusmumeagainstcolorectalcancerviasilencingrelaexpression AT chenrui networkpharmacologyandmoleculardockingbasedinvestigationprunusmumeagainstcolorectalcancerviasilencingrelaexpression |